CRITERIA FOR DRUG COVERAGE

naloxegol (Movantik®)

For patients not currently taking naloxegol AND for patients currently taking naloxegol tablets, non-formulary naloxegol (Movantik®) will be covered on the prescription drug benefit when the following criteria are met:

• Diagnosis of opioid induced constipation in an adult with an active opioid prescription
  - AND -

• Prescribed by an Oncologist, or a Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program, or after consultation with a Pain Management Specialist
  - AND -

• Patient has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action^ and route of administration: polyethylene glycol (MiraLAX), lactulose or sorbitol, senna, bisacodyl -AND- naldemedine (Symproic), a non-formulary, criteria based medication. Laxatives should be used in combination regularly to be effective in management of opioid-induced constipation.

^ e.g. osmotic with stimulant (polyethylene glycol and senna and/or bisacodyl suppository)